Effects of transcutaneous pulsed radiofrequency on patients with advanced cancer
Not Applicable
Completed
- Conditions
- <p>Advanced-stage colorectal, breast, prostate, or ovarian cancer no longer responding to systemic treatment</p>advanced cancer patients10027476
- Registration Number
- NL-OMON25071
- Lead Sponsor
- Radboud University Medical Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 15
Inclusion Criteria
1) = 18 years of age;
2) patients with advanced-stage colorectal, breast, prostate or ovarian cancer;
Exclusion Criteria
1) treatment with any cancer therapy, including but not limited to chemotherapy and radiation therapy, within 4 weeks before baseline;
2) in the use of critical measuring devices, large metal implants or active implants like a pacemaker;
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>Tumor markers<br /><br>- Carcinoembryonic antigen (CEA) for colorectal cancer;<br /><br>- Carcinoma antigen 15.3 (CA15.3) for breast cancer;<br /><br>- Prostate-specific antigen(PSA) for prostate cancer:<br /><br>- Carcinoma antigen 125 (CA125) for ovarian cancer.</p><br>
- Secondary Outcome Measures
Name Time Method <p>Pain intensity will be assessed using numeric rating scale (NRS).<br /><br>Quality of Life (QOL) will be assessed by<br /><br>-EORTC quality of life questionnaires QLQ-C30 and disease-specific modules;<br /><br>-Edmonton Symptom Assessment System (ESAS).</p><br>